<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812680</url>
  </required_header>
  <id_info>
    <org_study_id>15-9303-CE</org_study_id>
    <nct_id>NCT02812680</nct_id>
  </id_info>
  <brief_title>The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma</brief_title>
  <official_title>The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circulating microRNA (circ miRNA) and circulating tumor cell (CTC) levels are hypothesized to
      be associated with response to chemoradiation in patients undergoing treatment for locally
      advanced esophageal adenocarcinoma.

      The goal of this project is to assess the use of circulating microRNA (miRNA) and circulating
      tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, different groups have discovered that miRNAs can be detected in body fluids such as
      plasma, serum or saliva. These cell-free miRNAs are secreted by cells under different forms.
      Levels of these circulating miRNAs (circ miRNA), like tissue miRNA, were closely related to
      pathologies and could be used as diagnostic or prognostic tools for several pathologies,
      including cancer. Furthermore, a recent report showed that circ miRNAs released by tumor
      cells have the ability to transfer their metastatic potential to nonmetastatic cells. The
      detection and analysis of circulating miRNA represent a new step towards non-invasive
      diagnostic screening and early cancer detection.

      Circulating tumor cells also hold promise as biological markers, which can be assessed
      noninvasively. As more than 90% of cancer deaths are associated with metastasis, it is
      crucial to understand the mechanisms of dissemination of cancer cells. During the past
      decade, a multitude of techniques have been developed to track down and to characterize CTC.
      Clinical studies in various cancers reveal the potential of CTC as prognostic and predictive
      markers. The characterization of CTC will help to design personalized treatment to eradicate
      the sub-clones of the primary tumour, which give rise to metastasis. Also, the numbers of CTC
      in patient blood can be followed to monitor the efficacy of the neoadjuvant treatment.

      Most of the research in esophageal cancer has been done on squamous cell cancer as this is
      the dominant cell type worldwide. However, beginning the in 1980s Esophageal Adenocarcinoma
      (EAC) has increased in frequency such that it now represents 80% of esophageal cancer in
      North America and Europe. There is an urgent need to develop new techniques and diagnostic
      tests to combat EAC. By combining circ miRNA and CTC, we not only combine 2 promising
      clinical biomarkers, we will also be able to access new data that will complement tissue
      biopsy data. Furthermore, by acquiring a blood sample during various time points of patient
      treatment, we will be able to create a dynamic CTC and circ miRNA profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating microRNA (miRNA) as biomarkers of cancer and predictive markers for neoadjuvant therapy by using Human miRNA cards</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy by using CTC chips</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Esophageal Cancer Patients - Blood Draw</arm_group_label>
    <description>Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.</description>
    <arm_group_label>Esophageal Cancer Patients - Blood Draw</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Esophageal Cancer Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are at least 18 years of age

          -  Patients with Esophageal Adenocarcinoma who will undergo neo-adjuvant therapy with
             surgical resection.

          -  Patients with esophageal adenocarcinoma who will be treated with chemotherapy,
             chemotherapy and radiation or radiation alone

        Exclusion Criteria:

          -  Patients who are treated with surgery alone for esophageal cancer

          -  Patients who have a history of invasive cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail E Darling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandria Grindlay, BSc</last_name>
    <phone>416-634-7066</phone>
    <email>alexandria.grindlay@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frances Allison</last_name>
    <phone>416-340-5446</phone>
    <email>frances.allison@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Grindaly, BSc</last_name>
      <phone>416-634-7066</phone>
      <email>alexandria.grindlay@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Frances Allison</last_name>
      <phone>416-340-5446</phone>
      <email>frances.allison@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Gail E Darling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cancer.ca</url>
    <description>Canadian Cancer Statistics 2010</description>
  </link>
  <reference>
    <citation>Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol. 1994 Aug;21(4):403-10.</citation>
    <PMID>8042037</PMID>
  </reference>
  <reference>
    <citation>Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.</citation>
    <PMID>15761078</PMID>
  </reference>
  <reference>
    <citation>Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009 Mar;3(2 Suppl):S2-5.</citation>
    <PMID>19461918</PMID>
  </reference>
  <reference>
    <citation>Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014 Sep 20;32(27):2983-90.</citation>
    <PMID>25071104</PMID>
  </reference>
  <reference>
    <citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281-97. Review.</citation>
    <PMID>14744438</PMID>
  </reference>
  <reference>
    <citation>Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. Review.</citation>
    <PMID>19167326</PMID>
  </reference>
  <reference>
    <citation>Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet. 2008 Nov;9(11):831-42. doi: 10.1038/nrg2455. Review.</citation>
    <PMID>18852696</PMID>
  </reference>
  <reference>
    <citation>Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006 Apr;6(4):259-69. Review.</citation>
    <PMID>16557279</PMID>
  </reference>
  <reference>
    <citation>Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006 Nov;6(11):857-66. Review.</citation>
    <PMID>17060945</PMID>
  </reference>
  <reference>
    <citation>Lawrie CH, Cooper CD, Ballabio E, Chi J, Tramonti D, Hatton CS. Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy. Br J Haematol. 2009 May;145(4):545-8. doi: 10.1111/j.1365-2141.2009.07642.x. Epub 2008 Mar 2.</citation>
    <PMID>19298586</PMID>
  </reference>
  <reference>
    <citation>Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.</citation>
    <PMID>18663219</PMID>
  </reference>
  <reference>
    <citation>Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009 Sep 1;15(17):5473-7. doi: 10.1158/1078-0432.CCR-09-0736. Epub 2009 Aug 25.</citation>
    <PMID>19706812</PMID>
  </reference>
  <reference>
    <citation>Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012 Nov;37(11):460-5. doi: 10.1016/j.tibs.2012.08.003. Epub 2012 Sep 1.</citation>
    <PMID>22944280</PMID>
  </reference>
  <reference>
    <citation>Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 7;8(8):467-77. doi: 10.1038/nrclinonc.2011.76. Review.</citation>
    <PMID>21647195</PMID>
  </reference>
  <reference>
    <citation>Le MT, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L, Lieberman J. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014 Dec;124(12):5109-28. doi: 10.1172/JCI75695. Epub 2014 Nov 17.</citation>
    <PMID>25401471</PMID>
  </reference>
  <reference>
    <citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. Review.</citation>
    <PMID>21376230</PMID>
  </reference>
  <reference>
    <citation>Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014 Mar;11(3):129-44. doi: 10.1038/nrclinonc.2013.253. Epub 2014 Jan 21. Review.</citation>
    <PMID>24445517</PMID>
  </reference>
  <reference>
    <citation>Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015 Jan;7(1):1-11. doi: 10.15252/emmm.201303698. Review.</citation>
    <PMID>25398926</PMID>
  </reference>
  <reference>
    <citation>Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen E, Haider M, Darling G. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 2010 Sep 1;116(17):4023-32. doi: 10.1002/cncr.25349.</citation>
    <PMID>20533506</PMID>
  </reference>
  <reference>
    <citation>Underwood TJ, Derouet MF, White MJ, Noble F, Moutasim KA, Smith E, Drew PA, Thomas GJ, Primrose JN, Blaydes JP. A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. Biol Cell. 2010 Dec;102(12):635-44. doi: 10.1042/BC20100071.</citation>
    <PMID>20843300</PMID>
  </reference>
  <reference>
    <citation>Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S, Darling GE. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg. 2012 Oct;94(4):1094-102; discussion 1102-3. doi: 10.1016/j.athoracsur.2012.04.145. Epub 2012 Aug 29.</citation>
    <PMID>22939244</PMID>
  </reference>
  <reference>
    <citation>Derouet MF, Liu G, Darling GE. MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. PLoS One. 2014 Dec 31;9(12):e115589. doi: 10.1371/journal.pone.0115589. eCollection 2014.</citation>
    <PMID>25551563</PMID>
  </reference>
  <reference>
    <citation>Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, Thomas GJ. Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol. 2015 Feb;235(3):466-77. doi: 10.1002/path.4467.</citation>
    <PMID>25345775</PMID>
  </reference>
  <reference>
    <citation>Mohamadi RM, Besant JD, Mepham A, Green B, Mahmoudian L, Gibbs T, Ivanov I, Malvea A, Stojcic J, Allan AL, Lowes LE, Sargent EH, Nam RK, Kelley SO. Nanoparticle-mediated binning and profiling of heterogeneous circulating tumor cell subpopulations. Angew Chem Int Ed Engl. 2015 Jan 2;54(1):139-43. doi: 10.1002/anie.201409376. Epub 2014 Nov 5.</citation>
    <PMID>25377874</PMID>
  </reference>
  <reference>
    <citation>Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010 Mar 30;102(7):1174-9. doi: 10.1038/sj.bjc.6605608. Epub 2010 Mar 16.</citation>
    <PMID>20234369</PMID>
  </reference>
  <reference>
    <citation>Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan;112(1):55-9. doi: 10.1016/j.ygyno.2008.08.036. Epub 2008 Oct 26.</citation>
    <PMID>18954897</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

